erythematotelangiectatic

Erythematotelangiectatic describes a rosacea phenotype characterized by persistent facial redness (erythema) and visible superficial blood vessels (telangiectasia). It is one of the common rosacea subtypes and is often accompanied by episodic flushing.

Clinical features include central facial erythema, frequent or prolonged flushing, and telangiectasias on the cheeks and nose. Patients may report stinging, burning sensations, skin sensitivity, and mild edema. Triggers commonly include sun exposure, heat, spicy foods, alcohol, emotional stress, and certain skincare products.

Pathophysiology is not fully understood but involves abnormal vasomotor reactivity, chronic vascular dilation, and inflammatory processes. Demodex mites and neurovascular dysregulation have been proposed. The condition can occur with ocular rosacea in some individuals.

Management focuses on symptom control and trigger avoidance. Photoprotection with broad-spectrum sunscreen and gentle skincare are foundational. Topical therapies such as metronidazole, azelaic acid, or ivermectin can reduce inflammation. Maintenance vasoconstrictors, including brimonidine or oxymetazoline, can lessen persistent redness but may cause rebound redness. Systemic therapy, such as low-dose doxycycline, may help inflammatory symptoms. For visible vessels, vascular laser or intense pulsed light therapy can be effective.

Prognosis is chronic and relapsing; treatment aims to minimize symptoms and prevent flare-ups. Regular follow-up with a dermatologist is recommended.